Indústrias
Biopharmaceuticals & Rare Diseases
Todas as análises de Biopharmaceuticals & Rare Diseases — 3 análises.
38/100
Rocket Pharmaceuticals: Cash Buys Time, but Danon Still Has to Earn Back the Market's Trust
Rocket Pharmaceuticals (RCKT.US) is a rare-disease gene-therapy developer whose sole approved product, Kresladi, still generates no revenue, leaving cash and a $180 million voucher sale as the real near-term story. The stock trades near the value of its cash alone because the market still distrusts the pivotal Danon cardiac program after a 2025 clinical hold, even though Phase 1 data and a modified lower-dose cohort keep the thesis alive. Rating Hold: cash buys time, but Danon still has to earn back trust and Kresladi is too small to carry the valuation on its own.
45/100
BioMarin Pharmaceutical: A Rare-Disease Cash Engine in Transition
BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.
55/100
38Buffett
argenx (ARGX.US / ARGX.BR): Um Relatório Zen Horizon
A argenx é a líder global em terapias com anticorpos para doenças autoimunes raras e a pioneira first-in-class do campo dos inibidores de FcRn. Seu produto central, o Vyvgart (efgartigimod), já está aprovado em três indicações (gMG e CIDP globalmente, além de ITP no Japão), com cerca de 19000 pacientes em tratamento, vendas líquidas de USD 4.15 bilhões no FY2025 (+90%) e o primeiro lucro operacional positivo de sua história, de USD 1.05 bilhão. A Vision 2030 mira 50000 pacientes, 10 indicações aprovadas e 5 moléculas em Fase III. Classificação Observar: um ativo genuinamente forte cujo preço de USD 882.41 já precifica uma execução sem sobressaltos, de modo que a janela de entrada só se abre em uma correção para USD 720 ou abaixo.